創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
---|---|---|---|---|---|---|---|---|
20/09/08 | GEM221 | Anti-Globo H ADC | Cancer | i.v. | Antibody | Preclinical | High affinity, fast internalization, good in vitro cytotoxicity - Showed great tumor growth inhibition (>90%, 3 mg/kg) in HCC-1428 animal models without any body weight loss - Can be prepared reproducibly at gram scale. |
問合せ |
20/09/08 | GEM220 | Anti-Globo H Antibody | Breast Cancer | i.v. | Antibody | *Preclinical **Discovery | * Anti-Globo H monolonal antibody - Higher patient population in breast cancer (61%). - Anti-cancer efficacy demonstrated in breast cancer animal model through ADCC and CDC. **Anti-Globo H bispecific antibody - High correct pairing (>95%) -Target cell-dependent T cell activation (Better safety profile). - Anti-cancer efficacy demonstrated in breast cancer animal model through T cell-mediated cytotoxicity. |
問合せ |
20/09/08 | GEM219 | Anti-TIM-3 antibody | Cancer | i.v. | Antibody | Preclinical | GEM219 is a fully human anti-TIM-3 antibody with high affinity in vitro and cell-based binding assay. - The anti-TIM-3 antibodies are also highly functional in cellbased bioassay. - Some anti-TIM-3 antibodies have cross-species recognition ability to mouse TIM-3. - Animal efficacy studies are in progress |
問合せ |
20/09/08 | GEM218 | Anti- Human PD-L1 antibodies | Cancer | i.v. | Antibody | Preclinical | GEM218 is a novel monoclonal antibody that specifically binds to PD-L1 with high affinity and effectively blocks PD-1/PD-L1 interaction. - Can be well detected by the PD-1/PD-L1 Blockade Assay. - Novel binding epitopes. - Good potential for a companion diagnosis. - The efficacy and toxicity are studied in various in vitro and in vivo models |
問合せ |
20/09/08 | GEM217 | AXL Kinase Inhibitor | Cancer with high AXL expression | Oral | Small molecule | Preclinical | GEM217 is a selective AXL kinase inhibitor. - The chemical structure of GEM217 is distinguished from known AXL inhibitors. - Superior antitumor activity to reference compound BGB324, which is currently in phase II clinical trial for treating lung cancer. - Acceptable PK property and orally antitumor activity. |
問合せ |
20/09/08 | GEM215 | Globo H-Specific CAR-T Cells | Solid Tumor: breast cancer, gastric cancer and lung cancer | i.v. | Cell therapy | Discovery | Potential cell therapy for Globo H+ solid tumor. -Combination with anti-PD-L1 Ab overcomes PD-L1-mediated immune suppression on CAR-T cells in tumor microenvironment. -Anti PD-L1 Ab is able to induce bystander effect during Globo H CAR-T cell treatment. |
問合せ |
20/09/08 | GEM214 | Anti-K. pneumoniae (KP) Antibodies | Multiple Drug Resistant (MDR) Klebsiella pneumoniae (KP) infection | i.v. | Antibody | Preclinical | GEM214 is an anti-MDR therapeutic antibody against Klebsiella pneumoniae Infection. -A fully human mAb, has longer half-life and low immunogenicity. -Antibody Antibiotics Conjugate (AAC) of GEM214 shows dose dependent intracellularly bactericidal potency. |
問合せ |
20/09/08 | GEM213 | Anti-CSF-1R antibody | Cancer, PVNS (pigmented villonodular synovitis) | i.v. | Antibody | Preclinical | GEM213 is an antibody with high affinity and neutralizing ability. - GEM213 can potently inhibit Colony Stimulating Factor Receptor 1 (CSF-1R) in cellular contexts and has the potential to induce a therapeutic effect on macrophages. - GEM213 has unique CDR sequences and epitopes. - GEM213 is a promising new agent with potential to combine with immune checkpoint inhibitors to relief macrophage-dependent immune suppression and would yield clinical benefit. |
問合せ |
20/09/03 | GEM-CDV07 | CK2 inhibitor | COVID-19 | Oral | small molecule | IND# | - A promising therapeutic compound due to its dual impact on COVID-19 *Block stress granule disaggregation required for active viral replication *Reduce cytokine storm - GEM-CDV07 demonstrates potent anti-SARS-CoV-2 activity. - In process of filing for emergency IND (eIND) to U.S. FDA to test ten patients. #Phase 2 clinical trial is ongoing for other indication. |
問合せ |
20/08/26 | GEM212 | Antivirulent approach targeting antimicrobial resistance of Staphylococcus aureus infections | S. aureus and MRSA | Oral | Small molecule | Near completion of IND stage | An antivirulent, non-bactericidal small molecule drug candidate for S. aureus infections, including MRSA, in a first-in-class oral form. Potentially reduces the risk of S. aureus resistance. A new mechanism to enhance the killing action of neutrophils. Phase II clinical trials are planned across multiple indications; bacteremia, pneumonia, endocarditis, bone and joint infections. | 問合せ |